Table 1 demonstrates Radius Health Inc. and Spero Therapeutics Inc.’s top-line revenue, earnings per share and valuation.
The current Quick Ratio of Radius Health Inc. is 5 while its Current Ratio is 5.2. Meanwhile, Spero Therapeutics Inc. has a Current Ratio of 10.1 while its Quick Ratio is 10.1. Spero Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Radius Health Inc.
The next table highlights the shown recommendations and ratings for Radius Health Inc. and Spero Therapeutics Inc.
Radius Health Inc. has a 1.01% upside potential and a consensus target price of $24. On the other hand, Spero Therapeutics Inc.’s potential upside is 109.87% and its average target price is $28.5. The results from earlier shows that analysts belief suggest that Spero Therapeutics Inc. seems more appealing than Radius Health Inc.
Institutional investors owned 0% of Radius Health Inc. shares and 53.7% of Spero Therapeutics Inc. shares. 0.3% are Radius Health Inc.’s share owned by insiders. Competitively, 23.71% are Spero Therapeutics Inc.’s share owned by insiders.
Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Disclaimer: StocksBeat inform you that the data in this website is not necessarily real-time nor accurate. All prices are not provided by exchanges and prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Stocksbeat doesn`t bear any responsibility for any trading losses you might incur as a result of using the data.
Alarelin Acetate Exporter
Alpha Atriopeptin, Oxytocin Acetate, Abarelix Acetate - JYMed,https://www.peptidejymed.com/